- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00794560
Self-management of Low Molecular Weight Heparin Therapy
Self-management of Heparin Therapy - Drug Use Problems and Compliance With Self-injected Low Molecular Weight Heparin in Ambulatory Care
There is very little data available on compliance with self-injected low molecular weight heparins (LMWH), but what there is, definitely shows that compliance represents a significant problem. We therefore aim to a) record drug use problems of patients including compliance, b) develop a "SOP" for first instruction by a pharmacist and for subsequent pharmaceutical care and c) to compare intensive pharmaceutical care (intervention) vs. standard care (control) provided in the pharmacy to patients with a prescription for a LMWH as an outpatient treatment.
Hypothesis:
Intensive pharmaceutical care in ambulatory patients who self-inject low molecular weight heparins results in improved compliance, more safety and satisfaction as well as in fewer complications.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Patient recruitment in community pharmacies enables the testing of the feasibility of the interventions under daily-practice conditions and facilitates the recruitment of a larger number of patients.
Data collection:
- telephone interviews with structured questionnaires at the beginning and at the end of the therapy
- monitored self-injection in the study center or at patient's home (direct observation technique [DOT])
- compliance measurement: answers from patient interviews, comparing number of used syringes vs. number of prescribed syringes (analogue "pill count"), measuring residual volume in recycled syringes
- recording of the fine motor skills by the adapted "Disabilities of the Arm, Shoulder and Hand" questionnaire (DASH questionnaire)
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 4
Contactos e Locais
Locais de estudo
-
-
-
Basle, Suíça, CH-4031
- University Hospital of Basle, Switzerland
-
Bruderholz, Suíça, CH-4101
- Kantonsspital Baselland, Switzerland
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Patients are recruited from orthopedic clinics, an emergency department and from community pharmacies with a prescription for a LMWH as an outpatient treatment.
- self-application of the LMWH
german / english speaking
-> clinical setting:
Dalteparin
-> daily life setting:
- all LMWH (ready-to-use syringes)
- control group: self-application or application by another person (family member, medical person, etc.)
Exclusion Criteria:
- patient's home far away from study center
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: clinical setting: intervention
Recruitment of patients in the hospital into the randomized intervention group. Intervention is done by a trained pharmacist/Doctor of Philosophy-student in the study center (a pharmacy) or at patient's bedside in the hospital. Intervention: patient education |
Possible, individualized interventions:
|
Sem intervenção: clinical setting: standard care
Recruitment of patients in the hospital into the randomized control group (standard care in community pharmacy)
|
|
Experimental: daily life setting: intervention
Recruitment of patients in trained community pharmacies into the intervention group. Intervention is done by trained pharmacists. Intervention: patient education |
Possible, individualized interventions:
|
Sem intervenção: daily life setting: standard care
Recruitment of patients in community pharmacies into control group (standard care in community pharmacy)
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Drug Use Problems
Prazo: during the individual drug therapy, an average of 18 days
|
During a home visit and at her/his individual injection time, each patient was monitored when self-administering an s.c.
injection (directly observed therapy, DOT).
Score minimum = -2.00;
score maximum = +2.00 for the objective estimation of the application quality.
Higher score values represent better outcomes.
|
during the individual drug therapy, an average of 18 days
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Compliance
Prazo: at the end of the individual drug therapy, an average of 18 days
|
objectively determined by syringe count Therapy durations varied individually depending on the indication of the drug therapy (days to weeks).
|
at the end of the individual drug therapy, an average of 18 days
|
Patient Satisfaction
Prazo: at the end of the individual drug therapy, an average of 18 days
|
at the end of the individual drug therapy, an average of 18 days
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Kurt E. Hersberger, Prof. PhD, Pharmaceutical Care Research Group, University of Basle, Switzerland
Publicações e links úteis
Publicações Gerais
- Mengiardi S, Tsakiris DA, Molnar V, et al. Impact of Pharmaceutical Care on Self-Administration of Outpatient Low-Molecular-Weight Heparin Therapy. Pharmacology & Pharmacy 5: 372-385, 2014
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- NRA 630 00 23
- EKBB 95/07 (Outro identificador: ethics committee)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em patient education
-
Stanford UniversityNational Institute on Aging (NIA)Recrutamento
-
Brigham and Women's HospitalNational Institutes of Health (NIH); National Library of Medicine (NLM)DesconhecidoCâncer | Perda de audição | Cardiomiopatia hipertróficaEstados Unidos, Canadá
-
Advocate Health CareRetirado
-
Federal University of PelotasRecrutamentoCâncer de mamaBrasil
-
University of SaskatchewanRecrutamentoImagiologia Abdominal Adulto | Imagem abdominal pediátrica | Imagem obstétricaCanadá
-
University of SheffieldUniversity of Liverpool; University of Manchester; University of MelbourneAtivo, não recrutandoDesenvolvimento da linguagemReino Unido
-
The Christie NHS Foundation TrustManchester University NHS Foundation Trust; Aptus Clinical Ltd.; Zenzium Ltd.Concluído
-
University of OxfordBeijing Normal University; Beijing Stars and Rain Education Institute for AutismConcluídoAbuso infantil | Relações Pai-Filho | Transtorno do Espectro Autista | Paternidade | Problema de comportamento infantil | Relações familiares | Problema de saúde mentalChina
-
Stanford UniversityConcluídoTranstorno AutistaEstados Unidos
-
Chang Gung University of Science and TechnologyChang Gung Memorial Hospital; National Science and Technology CouncilAinda não está recrutando